Pliant Therapeutics (NASDAQ:PLRX) Posts Earnings Results

Pliant Therapeutics (NASDAQ:PLRX) posted its earnings results on Monday. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.99) by $0.17, Zacks reports.

Pliant Therapeutics Stock Performance

Shares of Pliant Therapeutics stock opened at $1.38 on Tuesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.26 and a quick ratio of 10.26. The firm has a market cap of $83.98 million, a price-to-earnings ratio of -0.41 and a beta of 1.03. The stock’s 50-day moving average is $9.08 and its 200-day moving average is $11.81. Pliant Therapeutics has a one year low of $1.37 and a one year high of $16.81.

Wall Street Analyst Weigh In

PLRX has been the subject of several research analyst reports. Leerink Partners downgraded Pliant Therapeutics from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $33.00 to $2.00 in a research report on Monday. Oppenheimer reiterated a “market perform” rating on shares of Pliant Therapeutics in a research report on Monday, February 10th. Stifel Nicolaus cut shares of Pliant Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday. HC Wainwright cut shares of Pliant Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, February 10th. Finally, JPMorgan Chase & Co. cut shares of Pliant Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, February 10th. Nine analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Pliant Therapeutics has a consensus rating of “Hold” and a consensus target price of $13.88.

Insider Activity at Pliant Therapeutics

In other news, General Counsel Mike Ouimette sold 10,230 shares of the business’s stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $10.99, for a total transaction of $112,427.70. Following the transaction, the general counsel now directly owns 70,544 shares in the company, valued at $775,278.56. The trade was a 12.66 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Bernard Coulie sold 52,419 shares of the company’s stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $11.20, for a total transaction of $587,092.80. Following the completion of the sale, the chief executive officer now directly owns 430,517 shares in the company, valued at approximately $4,821,790.40. The trade was a 10.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 91,855 shares of company stock valued at $1,026,628. 6.40% of the stock is owned by insiders.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.